Epileptic encephalopathies are a devastating group of severe childhood epilepsy disorders for which the cause is often unknown 1 . Here we report a screen for de novo mutations in patients with two classical epileptic encephalopathies: infantile spasms (n 5 149) and Lennox-Gastaut syndrome (n 5 115). We sequenced the exomes of 264 probands, and their parents, and confirmed 329 de novo mutations. A likelihood analysis showed a significant excess of de novo mutations in the 4,000 genes that are the most intolerant to functional genetic variation in the human population (P 5 2.9 3 10 23 ). Among these are GABRB3, with de novo mutations in four patients, and ALG13, with the same de novo mutation in two patients; both genes show clear statistical evidence of association with epileptic encephalopathy. Given the relevant site-specific mutation rates, the probabilities of these outcomes occurring by chance are P 5 4.1 3 10 210 and P 5 7.8 3 10 212 , respectively. Other genes with de novo mutations in this cohort include CACNA1A, CHD2, FLNA, GABRA1, GRIN1, GRIN2B, HNRNPU, IQSEC2, MTOR and NEDD4L. Finally, we show that the de novo mutations observed are enriched in specific gene sets including genes regulated by the fragile X protein (P , 10 28 ), as has been reported previously for autism spectrum disorders 2 .
Genetics is believed to have an important role in many epilepsy syndromes; however, specific genes have been discovered in only a small proportion of cases. Genome-wide association studies for both focal and generalized epilepsies have revealed few significant associations, and rare copy number variants explain only a few per cent of cases [3] [4] [5] [6] . An emerging paradigm in neuropsychiatric disorders is the major impact that de novo mutations have on disease risk 7, 8 . We searched for de novo mutations associated with epileptic encephalopathies, a heterogeneous group of severe epilepsy disorders characterized by early onset of seizures with cognitive and behavioural features associated with ongoing epileptic activity. We focused on two 'classical' forms of epileptic encephalopathies: infantile spasms and Lennox-Gastaut syndrome, recognizing that some patients with infantile spasms progress to Lennox-Gastaut syndrome.
Exome sequencing of 264 trios (Methods) identified 439 putative de novo mutations. Sanger sequencing confirmed 329 de novo mutations (Supplementary Table 2 ), and the remainder were either false positives, a result of B-cell immortalization, or in regions where the Sanger assays did not work ( Supplementary Table 3 ).
Across our 264 trios, we found nine genes with de novo single nucleotide variant (SNV) mutations in two or more probands (SCN1A, n 5 7; STXBP1, n 5 5; GABRB3, n 5 4; CDKL5, n 5 3; SCN8A, n 5 2; SCN2A, n 5 2; ALG13, n 5 2; DNM1, n 5 2; and HDAC4, n 5 2). Of these, SCN1A, STXBP1, SCN8A, SCN2A and CDKL5 are genes that have a previously established association with epileptic encephalopathy [9] [10] [11] [12] [13] [14] .
To assess whether the observations in the other genes implicate them as risk factors for epileptic encephalopathies, we determined the probability of seeing multiple mutations in the same gene given the sequencespecific mutation rate, size of the gene, and the number and gender of patients evaluated in this study (Methods). The number of observed de novo mutations in HDAC4 and DNM1 are not yet significantly greater than the null expectation. However, observing four unique de novo mutations in GABRB3 and two identical de novo mutations in ALG13 were found to be highly improbable (Table 1 and Fig. 1 ). We performed the same calculations on all of the genes with multiple de novo mutations observed in 610 control trios and found no genes with a significant excess of de novo mutations ( Supplementary Table 4 ). Although mutations in GABRB3 have previously been reported in association with another type of epilepsy 15 , and in vivo mouse studies suggest that GABRB3 haploinsufficiency is one of the causes of epilepsy in Angelman's syndrome 16 , our observations implicate it, for the first time, as a single-gene cause of epileptic encephalopathies and provide the strongest evidence to date for its association with any epilepsy. Likewise, ALG13, an X-linked gene encoding a subunit of the uridine diphosphate-N-acetylglucosamine transferase, was previously shown to carry a novel de novo mutation in a male patient with a severe congenital glycosylation disorder with microcephaly, seizures and early lethality 17 . Furthermore, the same ALG13 de novo mutation identified in this study was observed as a de novo mutation in an additional female patient with severe intellectual disability and seizures 18 .
Each trio harboured on average 1.25 confirmed de novo mutations, with 181 probands harbouring at least one. Considering only de novo SNVs, each trio harboured on average 1.17 de novo mutations (Supplementary Fig. 1 ). Seventy-two per cent of the confirmed de novo SNV mutations were missense and 7.5% were putative loss-of-function (splice donor, splice acceptor, or stop-gain mutations). Compared to rates of these classes of mutations previously reported in controls (69.4% missense and 4.2% putative loss-of-function mutations) 2, 19, 20 , we observed a significant excess of loss-of-function mutations in patients with infantile spasms and Lennox-Gastaut syndrome (exact binomial P 5 0.01), consistent with data previously reported in autism spectrum disorder 2, 8, 19, 20 .
A framework was recently established for testing whether the distribution of de novo mutations in affected individuals differs from the general population 8 . Here, we extend the simulation-based approach of ref. 8 by developing a likelihood model that characterizes this effect and describes the distribution of de novo mutations among affected individuals in terms of the distribution in the general population, and a set of parameters describing the genetic architecture of the disease. These parameters include the proportion of the exome sequence that can carry disease-influencing mutations (g) and the relative risk (c) of the mutations (Supplementary Methods). Consistent with what was reported in autism spectrum disorder 8 , we found no significant deviation in the overall distribution of mutations from expected (c 5 1 and/or g 5 0). It is, however, now well established that some genes tolerate protein-disrupting mutations without apparent adverse phenotypic consequences, whereas others do not 21 . To take this into account, we used a simple scoring system that uses polymorphism data in the human population to assign a tolerance score to every considered gene (Methods). We then found that genes with a known association with epileptic encephalopathy rank among the most intolerant genes using this scheme (Supplementary Table 8 ). We therefore evaluated the distribution of de novo mutations within these 4,264 genes that are within the 25th percentile for intolerance and found a significant shift from the null distribution (P 5 2.9 3 10 23 ). The maximum likelihood estimates of g (percentage of intolerant genes involved in epileptic encephalopathies) was 0.021 and c (relative risk) was 81, indicating that there are 90 genes among the intolerant genes that can confer risk of epileptic encephalopathies and that each mutation carries substantial risk. We also found that putatively damaging de novo variants in our cohort are significantly enriched in intolerant genes compared with control cohorts (Supplementary Methods).
We next evaluated whether the de novo mutations were drawn preferentially from six gene sets (Methods and Supplementary Table 10 ), including ion channels 22 , genes known to cause monogenic disorders with seizures as a phenotypic feature 23 , genes carrying confirmed de novo mutations in patients with autism spectrum disorder 2, 8, 19, 20 and in patients with intellectual disability 18, 24 , and FMRP-regulated genes. Taking into account the size of regions with adequate sequencing coverage to detect a de novo mutation (Methods), we found significant overrepresentation for all gene lists in our data ( Supplementary Table 10 ), and no over-representation in controls 2, 19, 20, 24 .
To determine possible interconnectivity among the genes carrying a de novo mutation, we performed a protein-protein interaction analysis and identified a single network of 71 connected proteins ( Fig. 2 and Supplementary Fig. 7 ). These 71 proteins include six encoded by OMIM reported epileptic encephalopathy genes (http://www.omim. org/) where we identified one or more de novo mutations among the epileptic encephalopathy patients in this study. Genes in this proteinprotein network were also found to have a much greater probability of overlap with the autism spectrum disorder 2, 8, 19, 20 and severe intellectual disability disorder 18,24 exome sequencing study genes, and with FMRPassociated genes, than genes not in this network ( Supplementary Table 11 ).
In support of a hypothesis that individual rare mutations in different genes may converge on biological pathways, we draw attention to six mutations that all affect subunits of the GABA (c-aminobutyric acid) ionotropic receptor (four in GABRB3, and one each in GABRA1 and GABRB1), and highlight two interactions: HNRNPU interacting with HNRNPH1, and NEDD4L (identified here) binding to TNK2, a gene previously implicated in epileptic encephalopathies 25 (Fig. 2 ). Although the HNRNPU mutation observed here is a small insertion/deletion variant (indel) in a splice acceptor site, and therefore probably results in a modified protein, the HNRNPH1 de novo mutation is synonymous and thus of unknown functional significance ( Supplementary Table 2 ). Notably, a minigene experiment indicates that this synonymous mutation induces skipping of exon 12 (Supplementary Methods).
Evaluation of the clinical phenotypes among patients revealed significant genetic heterogeneity underlying infantile spasms and Lennox-Gastaut syndrome, and begins to provide information about the range of phenotypes associated with mutations in specific genes (Supplementary Table 13 ). We identified four genes-SCN8A, STXBP1, DNM1 and GABRB3-with de novo mutations in both patients with infantile spasms and patients with Lennox-Gastaut syndrome. Although infantile spasms may progress to Lennox-Gastaut syndrome, in three of these cases the patients with Lennox-Gastaut syndrome did not initially present with infantile spasms, indicating phenotypic heterogeneity associated with mutations in these genes yet supporting the notion of shared genetic susceptibility. Notably, in multiple patients we identified de novo mutations in genes previously implicated in other neurodevelopmental conditions, and in some cases with very distinctive clinical presentations ( Supplementary Table 12 ). Most notably, we found a de novo mutation in MTOR, a gene recently found to harbour a causal variant in mosaic form in a case with hemimegalencephaly 26 . Our patient however showed no detectable structural brain malformation. Similarly, we found one patient with a de novo mutation in DCX and another with a de novo mutation in FLNA, previously associated with lissencephaly and periventricular nodular heterotopia, respectively 27, 28 ; neither patient had cortical malformations detected on magnetic resonance imaging.
In addition to de novo variants, we also screened for highly penetrant genotypes by identifying variants that create newly homozygous, compound heterozygous, or hemizygous genotypes in the probands that are not seen in parents or controls (Supplementary Methods). No inherited variants showed significant evidence of association. Additional studies evaluating a larger number of epileptic encephalopathy patients will be required to establish the role of inherited variants in the disease risk associated with infantile spasms and Lennox-Gastaut syndrome.
We have identified novel de novo mutations implicating at least two genes for epileptic encephalopathies, and also describe a genetic architecture that strongly suggests that we have identified additional causal mutations in genes intolerant to functional variation. Given that our sample size already shows many genes with recurrent mutations, it is clear that even modest increases in sample sizes will confirm many new genes now seen in only one of our trios. Our results also emphasize that it may be difficult to predict with confidence the responsible gene, even among known genes, based upon clinical presentation. This makes it clear that the future of genetic diagnostics in epileptic encephalopathies will need to focus on the genome as a whole as opposed to single genes or even gene panels. In particular, several of the genes with de novo mutations in our cohort have also been identified in patients with { Adjusted a is equivalent to 0.05/18,091 5 2.76 3 10 26 (*), 0.01/18,091 5 5.53 3 10 27 (**) and 0.001/18,091 5 5.53 3 10 28 (***). { Counts exclude three additional patients with an indel or splice site mutation as these are not accounted for in the mutability calculation.
1 Two de novo mutations occur at the same position. The probability of these special cases obtain P 5 7.77 3 10 212 and P 5 1.14 3 10 29 for ALG13 and SCN2A, respectively (Methods).
0.00000 0.00005 0.00010 0.00015 0.00020 Figure 1 | Heat map illustrating the probability of observing the specified number of de novo mutations in genes with the specified estimated mutation rate. The number of de novo mutations required to achieve significance is indicated by the solid red line. The superimposed dots reflect positions of all genes found to harbour multiple de novo mutations in our study. GABRB3, SCN1A, CDKL5 and STXBP1 have significantly more de novo mutations than expected. The positions indicated for ALG13 and SCN2A reflect only the fact that there are two mutations observed, not that there are two mutations affecting the same site (Methods).
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intellectual disability or autism spectrum disorder. Finally, and perhaps most importantly, this work suggests a clear direction for both drug development and treatment personalization in the epileptic encephalopathies, as many of these mutations seem to converge on specific biological pathways.
METHODS SUMMARY
All probands and family members were collected as part of the Epilepsy Phenome/ Genome Project (EPGP) cohort 29 ( Supplementary Table 1 ). Detailed inclusion and exclusion criteria are provided in Methods. Patient collection and sharing of specimens for research were approved by site-specific Institutional Review Boards.
We sequenced the exome of each trio, from DNA derived from primary cells (n 5 224 trios) or from lymphoblastoid cell lines (LCLs) in one or more family members (n 5 40 trios), using the TruSeq Exome Enrichment kit (Illumina). We aligned samples and called variants using established algorithms (Methods) and identified candidate de novo variants at sites included in the exons or splice sites of the consensus coding sequence (CCDS) as those called in the affected child and absent in both parents, despite each parent having at least tenfold coverage at the site. Variants created by the de novo mutation also had to be absent in our internal controls (n 5 436), as well as the approximately 6,500 samples represented in the Exome Variant Server (http://evs.gs.washington.edu/EVS), and had to pass visual inspection of alignment quality. Candidate de novo mutations were confirmed to be de novo mutations using Sanger sequencing. In all cases, primary DNA from the proband was used for the Sanger confirmation so that mutations appearing in the transformation process for the 40 trios sequenced from LCLs would be eliminated.
To determine whether our list of de novo mutations was preferentially located in genes contained in the six gene lists we calculated the proportion of CCDS de novo mutation opportunity space for each list (Additional Methods). A binomial probability calculation was used to determine whether the de novo mutations in CCDS transcripts identified in this cohort of epileptic encephalopathy patients were selectively enriched within the coding sequence of genes within a particular gene list ( Supplementary Table 10 ).
Ingenuity Pathway Analysis (Ingenuity Systems) was used to assess the connectivity of proteins harbouring a de novo mutation.
Full Methods and any associated references are available in the online version of the paper. de novo mutations in an infantile spasms or Lennox-Gastaut syndrome patient are known OMIM genes associated with epileptic encephalopathy (shaded circles). Five additional known OMIM genes associated with epileptic encephalopathy that were not found to be mutated in the 264 epileptic encephalopathy patients, but are involved in this network, are also shown (shaded circles with the gene underlined). The previously identified severe infantile epilepsy gene TNK2 is superimposed into this network (red circle).
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METHODS
Study subjects. Infantile spasms and Lennox-Gastaut syndrome patients evaluated in this study were collected through the Epilepsy Phenome/Genome Project (EPGP, http://www.epgp.org) 29 . Patients were enrolled across 23 clinical sites. Informed consent was obtained for all patients in accordance with the site-specific Institutional Review Boards. Phenotypic information has been centrally databased and DNA specimens stored at the Coriell Institute-NINDS Genetics Repository ( Supplementary Table 1 ). Infantile spasms patients were required to have hypsarrhythmia or a hypsarrhythmia variant on EEG. Lennox-Gastaut syndrome patients were required to have EEG background slowing or disorganization for age and generalized spike and wave activity of any frequency or generalized paroxysmal fast activity (GPFA). Background slowing was defined as ,8 Hz posterior dominant rhythm in patients over 3 years of age, and ,5 Hz in patients over 2 years of age. EEGs with normal backgrounds were accepted if the generalized spike and wave activity was 2.5 Hz or less and/or if GPFA was present. All patients were required to have no evidence of moderate-to-severe developmental impairment or diagnosis of autistic disorder or pervasive developmental disorder before the onset of seizures. Severe developmental delay was defined by 50% or more delay in any area: motor, social, language, cognition, or activities of living; or global delay. Mild delay was defined as delay of less than 50% of expected milestones in one area, or less than 30% of milestones across more than one area. All patients had no confirmed genetic or metabolic diagnosis, and no history of congenital TORCH infection, premature birth (before 32 weeks gestation), neonatal hypoxicischaemic encephalopathy or neonatal seizures, meningitis/encephalitis, stroke, intracranial haemorrhage, significant head trauma, or evidence of acquired epilepsy. All infantile spasms and Lennox-Gastaut syndrome patients had an MRI or CT scan interpreted as normal, mild diffuse atrophy or focal cortical dysplasia. (Our case with the mutation in HNRNPU had had a reportedly normal MRI but on review of past records, a second more detailed MRI was found showing small regions of periventricular nodular heterotopia.) To participate, both biological parents had to have no past medical history of seizures (except febrile or metabolic/toxic seizures).
A final diagnosis form was completed by the local site EPGP principal investigator based on all collected information. A subset of cases was reviewed independently by two members of the EPGP Data Review Core to ensure data quality and consistency. All EEGs were reviewed by a site investigator and an EEG core member to assess data quality and EEG inclusion criteria. EEGs accepted for inclusion were then reviewed and scored by two EEG core members for specific EEG phenotypic features. Disagreements were resolved by consensus conference among two or more EEG core members before the EEG data set was finalized. MRI scans were reviewed by local investigators and an MRI core member to exclude an acquired symptomatic lesion.
Exome-sequenced unrelated controls (n 5 436) used to ascertain mutation frequencies were sequenced in the Center for Human Genome Variation as part of other genetic studies. Exome sequencing, alignment and variant calling. Exome sequencing was carried out within the Genomic Analysis Facility in the Center for Human Genome Variation (Duke University). Sequencing libraries were prepared from primary DNA extracted from leukocytes of parents and probands using the Illumina TruSeq library preparation kit following the manufacturer's protocol. Illumina TruSeq Exome Enrichment kit was used to selectively amplify the coding regions of the genome according to the manufacturer's protocol. Six individual barcoded samples (two complete trios) were sequenced in parallel across two lanes of an Illumina HiSeq 2000 sequencer.
Alignment of the sequenced DNA fragments to Human Reference Genome (NCBI Build 37) was performed using the Burrows-Wheeler Alignment Tool (BWA) (version 0.5.10). The reference sequence we use is identical to the 1000 Genomes Phase II reference and it consists of chromosomes 1-22, X, Y, MT, unplaced and unlocalized contigs, the human herpesvirus 4 type 1 (NC_007605), and decoy sequences (hs37d5) derived from HuRef, Human Bac and Fosmid clones and NA12878.
After alignments were produced for each individual separately using BWA, candidate de novo variants were jointly called with the GATK Unified Genotyper for all family members in a trio. Loci bearing putative de novo mutations were extracted from the variant call format files (VCFs) that met the following criteria:
(1) the read depth in both parents should be greater than or equal to 10; (2) the depth of coverage in the child should be at least one-tenth of the sum of the coverage in both parents; (3) for de novo variants, less than 5% of the reads in either parent should carry the alternate allele; (4) at least 25% of the reads in the child should carry the alternate allele; (5) the normalized, phred-scaled likelihood (PL) scores for the offspring genotypes AA, AB and BB, where A is the reference allele and B is the alternate allele, should be .20, 0 and .0, respectively; (6) the PL scores for both parents should be 0, .20 and .20; (7) at least three variant alleles must be observed in the proband; and (8) the de novo variant had to be located in a CCDS exon targeted by the exome enrichment kit. PL scores are assigned such that the most likely genotype is given a score of 0, and the score for the other two genotypes represent the likelihood that they are not the true genotypes. SnpEff (version 3.0a) was used to annotate the variants according to Ensembl (version 69) and consensus coding sequencing (CCDS release 9, GRCh37.p5) and limited analyses to exonic or splice site (2 bp flanking an exon) mutations. All candidate de novo mutations that were absent from population controls, including a set of 436 internally sequenced controls and the ,6,500 individuals whose single nucleotide variant data are reported in the Exome Variant Server, NHLBI Exome Sequencing Project (http:// evs.gs.washington.edu/EVS/; August 2012) were also visually inspected using Integrative Genomics Viewer (IGV). All candidate de novo mutations were confirmed with Sanger sequencing of the relevant proband and parents. For comparison, we also called de novo variants from probands and parents individually for a subset of trios. Using this individual calling approach we identified and confirmed an additional 46 de novo mutations. These were included in all the downstream de novo mutation analyses. Calculation of gene-specific mutation rate. Point mutation rates were scaled to per base pair, per generation, based on the human genome sequences matrix 30 (provided by S. Sunyaev and P. Polak), and the known human average genome de novo mutation rate (1.2 3 10 28 ) 31 . The mutation rate (M) of each gene was calculated by adding up point mutation rates in effectively captured CCDS regions in the offspring of trios, and then dividing by the total trio number (S 5 264). The P value was calculated as [1 2 Poisson cumulative distribution function (x 2 1, l)], where x is the observed de novo mutation number for the gene, and l is calculated as 2SM for genes on autosome or (2f 1 m)M for genes on chromosome X (f and m are the number of sequenced female and male probands, respectively). Genes on Y chromosome were not part of these analyses. Two de novo mutations in gene ALG13 are at the same position, likewise in gene SCN2A. We calculated the probability of this special case as [1 2 Poisson cumulative distribution function (1, (2f 1 m)r)], where r reflects the point mutation rate on that specific de novo mutation position. Further investigations indicated that it is unlikely for these de novo mutations, which occur at the same site across distinct probands, to have been caused by sequencing or mapping errors (Supplementary Methods). Calculation of mutation tolerance for HGNC genes. To assign quantitatively a mutation tolerance score to genes in the human genome (HGNC genes), we calculated an empirical penalty based on the presence of common functional variation using the aggregate sequence data available from the 6,503 samples reported in the Exome Variant Server, NHLBI Exome Sequencing Project (http://evs.gs.washington. edu/EVS/; accessed August 2012). We first filtered within the EVS database and eliminated from further consideration genes where the number of tenfold average covered bases was less than 70% of its total extent. In calculating a score, we focused on departures from the average common functional variant frequency spectrum, corrected for the total mutation burden in a gene. We construct this score as follows. Let Y be the total number of common, minor allele frequency .0.1%, missense and nonsense (including splice) variants and let X be total number of variants (including synonymous) observed within a gene. We regress Y on X and take the studentized residual as the score (S). Thus, the raw residual is divided by an estimate of its standard deviation and thus account for differences in variability that comes with differing mutational burdens. S measures the departure from the average number of common functional mutations found in genes with a similar amount of mutational burden. Thus, when S 5 0 the gene has the average number of common functional variants given its total mutational burden. Genes where S , 0 have less common functionals than average for their mutational burden and thus, would seem to be less tolerant of functional mutation, indicating the presence of weak purifying selection. We further investigated how different 'intolerance' thresholds of S captured known epileptic encephalopathy genes ( Supplementary Table 8 ). Supplementary Fig. 6 illustrates how different percentiles of S lead to the classification of different proportions of the known epileptic encephalopathy genes as 'intolerant'. Note that ARX is not in these analyses as this gene did not meet a 70% of gene coverage threshold. The dashed vertical line in Supplementary Fig. 6 illustrates the 25th percentile of S and shows that using this threshold results in 12 out of the 14 assessed known genes being considered 'intolerant'. On the basis of this analysis, we used this 25th percentile threshold in classifying genes as intolerant in all subsequent analyses. Supplementary Table 9 lists the 25th percentile of most intolerant genes that had Sanger confirmed de novo mutations among the infantile spasms/Lennox-Gastaut syndrome probands. Defining the CCDS opportunity space for detecting de novo mutations. For each trio, we defined callable exonic bases that had the opportunity for identification of a coding de novo mutation, by restricting to bases where each of the three family members had at least tenfold coverage, obtained a multi-sampling (GATK) raw phred-scaled confidence score of $20 in the presence or absence of a variant, and were within the consensus coding sequence (CCDS release 9, GRCh37.p5) or within the two base pairs at each end of exons to allow for splice acceptor and donor variants. Using these three criteria, the average CCDS-defined de novo mutation opportunity space across 264 trios was found to be 28.84 6 0.92 Mb (range of 25.46-30.25 Mb).
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